Abstract library

2084 results for "FDG-PET positive and-PET negative SI-NET patients".
#1412 MiR-196a Is Specifically Regulated in FDG-PET Positive and Negative Small Intestinal Neuroendocrine Tumor Patients at Late Stage of Disease
Introduction: This collaborative research plan aims at elucidating the glycolytic metabolism in advanced FDG-PET positive (+) and FDG-PET negative (-) small intestinal neuroendocrine tumor (SI-NET) patients treated with Lutetium peptide receptor radionuclide therapy (177Lu-PRRT).
Conference: 13th Annual ENETS conference 2016 (2016)
Category: ...none of the above
Presenting Author: PhD Valeria Giandomenico
#651 Additional Value of New Molecular Imaging Tracers in the Detection of Recurrent/Residual Disease in Patients with Neuroendocrine Tumors
Introduction: Recent studies have proposed new molecular imaging tracers, such as 18F-DOPA and 68Ga-DOTANOC, for the detection of recurrent/residual neuroendocrine tumors (NET) in case of negative conventional imaging modalities.
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Andrea Lania
#3000 Patients with Somatostatin Receptor Type 2-Negative Neuroendocrine Tumors Have Sustained Inferior Survival Rates in a Propensity Score-Matched Analysis
Introduction: Sufficient expression of somatostatin receptor type 2 (SST2) in neuroendocrine tumors (NETs) is crucial for treatment with unlabelled somatostatin analogues (SSAs), or peptide receptor radionuclide therapy (PRRT) using radio-labelled SSAs. Impaired prognosis has been described for SST2-negative NET patients, however studies comparing matched SST2-positive and -negative subjects are missing.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Dr Julie Refardt
#90 The prognostic value of FDG-PET scan in neuroendocrine tumors: a retrospective analysis of 46 patients treated in one center
Introduction: Neuroendocrine tumors (NETs) are rare and generally indolent. For diagnostic purposes, the sensitivity of FDG-PET scan is known to be low in this setting, though when positive, its prognostic value is not well-defined in NET.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Ivan Borbath
#2074 The Risk of Secondary Primary Colorectal Adenocarcinomas Is Not Increased among Patients with Gastroenteropancreatic Neuroendocrine Tumors – A Nationwide Population Based Study
Introduction: It has been suggested that secondary primary colorectal adenocarcinomas (SPCA) occur more often than normal in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Epidemiology/Natural history/Prognosis- Registries, nationwide and regional surveys
Presenting Author: Student Tobias Stemann Lau
#1909 68Ga-DOTA-TOC and 18F-FDG-PET/CT in the Follow-up of NET Patients treated with First Full PRRT
Introduction: Only few studies have correlated 18F-FDG and SSTR imaging with NET grade.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Prof.Dr. Margarida Rodrigues
Keywords: 68Ga-PET, FDG
#56 Somatostatinreceptor scintigraphy with Tc-99m-tektrotyd in patients with neuroendocrine tumors: correlation with immunohistochemistry
Introduction: Somatostatin receptor scintigraphy (STRS) with Tc-99m-tektrotyd has been used in the past few years for diagnosis and staging of neuroendocrine tumors (NETs). A number of clinicopathologic criteria proved to be useful predictors of malignant behavior of these tumors. Immunohistochemical markers for NETs include cell proliferation (Ki-67 index) and neuroendocrine markers such as chromogranin A (CgA) and synaptophysin.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Prof Margarida Rodrigues
#675 Olfactory Receptor 51E1 is a Potential Novel Target for Diagnosis and Treatment of Somatostatin Receptor Negative Lung Carcinoid Patients
Introduction: Somatostatin receptor (SSTR) expression may be used for diagnosis and therapy of lung carcinoids. However, novel targets are requested.
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: Tao Cui
#1158 A Phase II Study of Everolimus in Patients with FDG-PET Positive Intermediate Grade (Ki67 3-20%) Pancreatic Neuroendocrine Tumor
Introduction: The RADIANT-3 trial showed Everolimus (EV), as active in patients (pts) with progressive well/intermediate grade PNETs. Intermediate/grade 2 (Ki67 3-20%) PNETs have variable biology. FDG-PET avidity is an independent negative factor for survival, consistent with aggressive disease biology- but such imaging is not used to select treatment as in the case of the RADIANT 3 trial.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Medical treatment - Targeted therapies
Presenting Author: ASSOC PROF Michael Michael
Authors: Michael M, Pavlakis N, Wyld D, Link E, ...
Keywords: everolimus, FDG-PET
#1630 The Positive Expression of PD-L1/PD-1 in Gastroenteropancreatic Neuroendocrine Neoplasias Correlates with Prognosis
Introduction: The incidence of Neuroendocrine Neoplasias (NENs) is increasing and their pathological characteristics, varied between races. However, the epidemiology of GEP-NENs in Chinese patients remains poorly characterized especially for the expression of important immune checkpoint protein PD1 and PD-L1.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Pathology, grading, staging
Presenting Author: Wu Yinying
Authors: Yinying W, Chuying W, ...